To determine whether increased Smurf2 expression predicts tumor progression and poorer survival in patients who receive chemoRT, we selected a cohort of patients with stage III NSCLC, for whom platinum-based chemotherapy or chemoRT is the standard of care, from the TCGA database35. This evidence concerns the gene SMURF2 and neoplasm.